Published in Medical Letter on the CDC and FDA, November 16th, 2003
This patch, under the proposed name Menostar, delivers nearly 50% less estrogen per day than the lowest dose transdermal estrogen product currently available for the prevention of osteoporosis.
Upon approval, Menostar will offer healthcare providers with a new treatment option that delivers an ultra-low dose of plant-based estrogen, which will not require a concomitant progestin,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.